Agents and Actions

, Volume 6, Issue 4, pp 468–475 | Cite as

Biological effects of cyclosporin A: A new antilymphocytic agent

  • J. F. Borel
  • Camille Feurer
  • H. U. Gubler
  • H. Stähelin
Immunosuppression and Inflammation Research Reports


The fungus metabolite cyclosporin A is a small peptide acting as a novel antilymphocytic agent. It strongly depressed appearance of both direct and indirect plaque-forming cells and produced a clear dose-dependent inhibition of haemagglutinin formation in mice upon oral administration. Skin graft rejection in mice and graft-versus-host disease in mice and rats were considerably delayed by cyclosporin A which also prevented the occurrence of paralysis in rats with experimental allergic encephalomyelitis. This compound was not only highly effective in preventing development of Freund's adjuvant arthritis, but in addition improved the symptoms in rats with established arthritis, although it is inactive in acute inflammation. This new agent contrasts with other immunosuppressives and cytostatic drugs in its weak myelotoxicity. Experimental evidence suggests that cyclosporin A, rather than being cytostatic or lympholytic, affects an early stage of mitogenic triggering of the immunocompetent lymphoid cell.


Arthritis Cyclosporin Lymphoid Cell Skin Graft Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    A. Rüegger, M. Kuhn, H. Lichti, H. Loosli, R. Huguenin, C. Quiquerez andA. von Wartburg,Cyclosporin A, ein immunosuppressiv wirksamer Peptidmetabolit aus Trichoderma polysporum (Link ex Pers.) Rifai, Helv. chim. Acta (in press).Google Scholar
  2. [2]
    J.F. Borel,Comparison of the Immune Response to Sheep Erythrocytes, Tetanus Toxoid and Endotoxin in Different Strains of Mice, Agents and Actions4, 277–285 (1974).CrossRefPubMedGoogle Scholar
  3. [3]
    G. Takatsy,The Use of Spiral Loops in Serological and Virological Micromethods, Acta microbiol. Hung.3, 191–202 (1956).Google Scholar
  4. [4]
    R.E. Billingham andP. B. Medawar,The Technique of Free Skin Grafting in Mammals, J. exp. Biol.28, 385–402 (1951).Google Scholar
  5. [5]
    A. H. Owens andG. W. Santos,The Effect of Cytotoxic Drugs on Graft-versus-Host Disease in Mice, Transplantation11, 378–382 (1971).PubMedGoogle Scholar
  6. [6]
    R.A.C., Hughes andJ. Stedronska,The Susceptibility of Rat Strains to Experimental Allergic Encephalomyelitis, Immunology24, 879–884 (1973).PubMedGoogle Scholar
  7. [7]
    C.A. Winter andG.W. Nuss,Treatment of Adjuvant Arthritis in Rats with Anti-Inflammatory Drugs, Arthritis Rheum.9, 394–404 (1966).PubMedGoogle Scholar
  8. [8]
    R. Feissly andH. Luedin,Microscopie par contrastes de phases, Rev. Hémat.4, 481–490 (1949).Google Scholar
  9. [9]
    R.P. Lisak andP.O. Behan,Experimental Autoimmune Demyelinating Diseases: Experimental Allergic Encephalomyelitis and Experimental Allergic Neuritis, Biomedicine22, 81–87 (1975).PubMedGoogle Scholar

Copyright information

© Birkhäuser-Verlag 1976

Authors and Affiliations

  • J. F. Borel
    • 1
  • Camille Feurer
    • 1
  • H. U. Gubler
    • 1
  • H. Stähelin
    • 1
  1. 1.Biological and Medical Research Division Sandoz LtdBasleSwitzerland

Personalised recommendations